Symbols / ONCY
ONCY Chart
About
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 121.60M |
| Enterprise Value | 109.49M | Income | -35.27M | Sales | — |
| Book/sh | 0.00 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | — |
| P/E | — | Forward P/E | -4.57 | PEG | — |
| P/S | — | P/B | 1547.52 | P/C | — |
| EV/EBITDA | -3.14 | EV/Sales | — | Quick Ratio | 1.62 |
| Current Ratio | 1.84 | Debt/Eq | 726.09 | LT Debt/Eq | — |
| EPS (ttm) | -0.31 | EPS next Y | -0.25 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -111.21% |
| ROE | -7.69% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 107.61M |
| Shs Float | 103.74M | Short Float | 3.68% | Short Ratio | 3.08 |
| Short Interest | — | 52W High | 1.51 | 52W Low | 0.33 |
| Beta | 0.95 | Avg Volume | 1.19M | Volume | 3.23M |
| Target Price | $5.53 | Recom | Buy | Prev Close | $1.06 |
| Price | $1.13 | Change | 6.60% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.53
Mean price target
2. Current target
$1.13
Latest analyst target
3. DCF / Fair value
$-2.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.13
Low
$3.04
High
$9.98
Mean
$5.53
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-17 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-13 | init | Lake Street | — → Buy | $7 |
| 2025-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-16 | down | Jones Trading | Buy → Hold | — |
| 2025-03-10 | main | Maxim Group | Buy → Buy | $3 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-10 | main | RBC Capital | Outperform → Outperform | $5 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-09-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-04 | init | Raymond James | — → Outperform | $3 |
| 2024-03-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-01-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-01-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-11-13 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-29 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
- Oncolytics plots sub-100 patient trial seeking FDA approval in rare anal cancer - Stock Titan ue, 24 Feb 2026 14
- Oncolytics to stop enrollments for GIT cancer trial (ONCY) - Seeking Alpha ue, 24 Feb 2026 19
- $ONCY stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Wed, 21 Jan 2026 08
- ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits Wed, 04 Feb 2026 08
- Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Wed, 03 Dec 2025 08
- Patricia Andrews Acquires 35,400 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock - MarketBeat Fri, 13 Feb 2026 08
- Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - PR Newswire Fri, 08 Aug 2025 07
- $ONCY stock is up 23% today. Here's what we see in our data. - Quiver Quantitative Fri, 13 Feb 2026 19
- New leaders join cancer trial firm Oncolytics to steer GI studies - Stock Titan Wed, 14 Jan 2026 08
- All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - Yahoo Finance Wed, 19 Nov 2025 08
- Insider Purchase: Chief Executive Officer of $ONCY Buys 29,500 Shares - Quiver Quantitative Fri, 13 Feb 2026 12
- Oncolytics Biotech (Nasdaq: ONCY) sets Jan. 15 vote on Nevada reincorporation - Stock Titan ue, 09 Dec 2025 08
- Oncolytics Biotech (NASDAQ:ONCY) Director Purchases $34,000.00 in Stock - MarketBeat Fri, 13 Feb 2026 08
- Oncolytics Biotech (NASDAQ:ONCY) Insider Purchases $25,456.00 in Stock - MarketBeat Fri, 13 Feb 2026 08
- Cancer drug pelareorep could stay protected into 2044 under new patents - Stock Titan hu, 08 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 35400 | 30292 | — | Purchase at price 0.86 per share. | ANDREWS PATRICIA S. | Director | — | 2026-02-12 00:00:00 | D |
| 1 | 30000 | 25338 | — | Purchase at price 0.84 per share. | PISANO WAYNE | Director | — | 2026-02-12 00:00:00 | D |
| 2 | 100000 | 83454 | — | Purchase at price 0.83 - 0.85 per share. | SEIZINGER BERND R. | Director | — | 2026-02-12 00:00:00 | D |
| 3 | 25000 | 21240 | — | Purchase at price 0.85 per share. | BROWN DEBORAH M | Director | — | 2026-02-12 00:00:00 | D |
| 4 | 12000 | 10104 | — | Purchase at price 0.84 per share. | LOOK KIRK J | Chief Financial Officer | — | 2026-02-12 00:00:00 | D |
| 5 | 12132 | 10033 | — | Purchase at price 0.83 per share. | HEINEMAN THOMAS PH.D. | Officer | — | 2026-02-12 00:00:00 | D |
| 6 | 10000 | 8298 | — | Purchase at price 0.83 per share. | HAGERMAN ALLISON | Officer | — | 2026-02-12 00:00:00 | D |
| 7 | 35100 | 29521 | — | Purchase at price 0.84 per share. | KELLY JARED RYAN | Chief Executive Officer | — | 2026-02-12 00:00:00 | D |
| 8 | 29600 | 25418 | — | Purchase at price 0.86 per share. | AROMANDO ANDREW P | Officer | — | 2026-02-11 00:00:00 | D |
| 9 | 100000 | 103770 | — | Purchase at price 1.04 per share. | SEIZINGER BERND R. | Director | — | 2026-01-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 330.45K | 1.92M | 431.15K | -31.54K |
| TaxRateForCalcs | 0.15 | 0.40 | 0.26 | 0.27 |
| NormalizedEBITDA | -36.76M | -38.20M | -28.18M | -25.66M |
| TotalUnusualItems | 2.20M | 4.81M | 1.65M | -119.00K |
| TotalUnusualItemsExcludingGoodwill | 2.20M | 4.81M | 1.65M | -119.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -31.71M | -27.75M | -24.84M | -26.30M |
| ReconciledDepreciation | 424.00K | 403.00K | 392.00K | 452.00K |
| EBITDA | -34.56M | -33.39M | -26.53M | -25.78M |
| EBIT | -34.98M | -33.79M | -26.92M | -26.23M |
| NetInterestIncome | 1.20M | 1.33M | 528.00K | 99.00K |
| InterestIncome | 1.20M | 1.33M | 528.00K | 99.00K |
| NormalizedIncome | -33.58M | -30.64M | -26.05M | -26.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -31.71M | -27.75M | -24.84M | -26.30M |
| TotalExpenses | 34.98M | 33.79M | 26.92M | 26.23M |
| TotalOperatingIncomeAsReported | -26.23M | |||
| DilutedAverageShares | 76.48M | 67.62M | 58.03M | 53.51M |
| BasicAverageShares | 76.48M | 67.62M | 58.03M | 53.51M |
| DilutedEPS | -0.41 | -0.41 | -0.43 | -0.49 |
| BasicEPS | -0.41 | -0.41 | -0.43 | -0.49 |
| DilutedNIAvailtoComStockholders | -31.71M | -27.75M | -24.84M | -26.30M |
| NetIncomeCommonStockholders | -31.71M | -27.75M | -24.84M | -26.30M |
| NetIncome | -31.71M | -27.75M | -24.84M | -26.30M |
| NetIncomeIncludingNoncontrollingInterests | -31.71M | -27.75M | -24.84M | -26.30M |
| NetIncomeContinuousOperations | -31.71M | -27.75M | -24.84M | -26.30M |
| TaxProvision | 130.00K | 97.00K | 84.00K | 49.00K |
| PretaxIncome | -31.58M | -27.66M | -24.75M | -26.25M |
| OtherIncomeExpense | 2.20M | 4.81M | 1.65M | -119.00K |
| GainOnSaleOfSecurity | 2.20M | 4.81M | 1.65M | -119.00K |
| NetNonOperatingInterestIncomeExpense | 1.20M | 1.33M | 528.00K | 99.00K |
| InterestIncomeNonOperating | 1.20M | 1.33M | 528.00K | 99.00K |
| OperatingIncome | -34.98M | -33.79M | -26.92M | -26.23M |
| OperatingExpense | 34.98M | 33.79M | 26.92M | 26.23M |
| OtherOperatingExpenses | 13.31M | |||
| DepreciationAmortizationDepletionIncomeStatement | 424.00K | 403.00K | 392.00K | 452.00K |
| DepreciationAndAmortizationInIncomeStatement | 424.00K | 403.00K | 392.00K | 452.00K |
| DepreciationIncomeStatement | 424.00K | 403.00K | 392.00K | 452.00K |
| ResearchAndDevelopment | 21.65M | 17.71M | 15.43M | 12.92M |
| SellingGeneralAndAdministration | 12.91M | 15.68M | 11.10M | 12.86M |
| GeneralAndAdministrativeExpense | 12.91M | 15.68M | 11.10M | 12.86M |
| OtherGandA | 9.06M | 11.73M | 7.22M | 11.12M |
| SalariesAndWages | 3.85M | 3.94M | 3.88M | 1.74M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 80.02M | 74.42M | 61.33M | 55.04M |
| ShareIssued | 80.02M | 74.42M | 61.33M | 55.04M |
| TotalDebt | 1.06M | 423.00K | 373.00K | 655.00K |
| TangibleBookValue | 5.98M | 27.56M | 26.50M | 36.10M |
| InvestedCapital | 5.98M | 27.56M | 26.50M | 36.10M |
| WorkingCapital | 12.19M | 33.94M | 31.74M | 42.21M |
| NetTangibleAssets | 5.98M | 27.56M | 26.50M | 36.10M |
| CapitalLeaseObligations | 1.06M | 423.00K | 373.00K | 655.00K |
| CommonStockEquity | 5.98M | 27.56M | 26.50M | 36.10M |
| TotalCapitalization | 5.98M | 27.56M | 26.50M | 36.10M |
| TotalEquityGrossMinorityInterest | 5.98M | 27.56M | 26.50M | 36.10M |
| StockholdersEquity | 5.98M | 27.56M | 26.50M | 36.10M |
| OtherEquityInterest | 3.62M | |||
| GainsLossesNotAffectingRetainedEarnings | 961.00K | 544.00K | 662.00K | 388.00K |
| OtherEquityAdjustments | 961.00K | 544.00K | 662.00K | 388.00K |
| RetainedEarnings | -477.71M | -446.00M | -418.25M | -393.42M |
| AdditionalPaidInCapital | 44.54M | 42.12M | 40.05M | 34.16M |
| CapitalStock | 438.19M | 430.91M | 404.04M | 391.35M |
| CommonStock | 438.19M | 430.91M | 404.04M | 391.35M |
| TotalLiabilitiesNetMinorityInterest | 14.20M | 11.26M | 10.83M | 9.78M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.52M | 7.02M | 6.89M | 7.09M |
| NonCurrentDeferredLiabilities | 6.73M | 6.73M | 6.73M | 6.73M |
| NonCurrentDeferredRevenue | 6.73M | 6.73M | 6.73M | 6.73M |
| LongTermDebtAndCapitalLeaseObligation | 787.00K | 290.00K | 157.00K | 361.00K |
| LongTermCapitalLeaseObligation | 787.00K | 290.00K | 157.00K | 361.00K |
| CurrentLiabilities | 6.69M | 4.24M | 3.94M | 2.69M |
| OtherCurrentLiabilities | 1.62M | 532.00K | 79.00K | 408.00K |
| CurrentDebtAndCapitalLeaseObligation | 277.00K | 133.00K | 216.00K | 294.00K |
| CurrentCapitalLeaseObligation | 277.00K | 133.00K | 216.00K | 294.00K |
| PayablesAndAccruedExpenses | 4.79M | 3.57M | 3.65M | 1.99M |
| CurrentAccruedExpenses | 3.71M | 2.49M | 1.40M | 1.39M |
| Payables | 1.09M | 1.08M | 2.25M | 594.00K |
| AccountsPayable | 1.09M | 1.08M | 2.25M | 594.00K |
| TotalAssets | 20.19M | 38.82M | 37.33M | 45.88M |
| TotalNonCurrentAssets | 1.31M | 647.00K | 1.65M | 976.00K |
| NonCurrentPrepaidAssets | 0.00 | 998.00K | 0.00 | |
| NetPPE | 1.31M | 647.00K | 652.00K | 976.00K |
| AccumulatedDepreciation | -632.00K | -695.00K | -614.00K | -521.00K |
| GrossPPE | 1.94M | 1.34M | 1.27M | 1.50M |
| Leases | 1.08M | 596.00K | 527.00K | 812.00K |
| OtherProperties | 3.00K | 62.00K | 62.00K | 62.00K |
| MachineryFurnitureEquipment | 856.00K | 684.00K | 677.00K | 623.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 18.88M | 38.17M | 35.68M | 44.90M |
| HedgingAssetsCurrent | 980.00K | 0.00 | ||
| PrepaidAssets | 1.89M | 3.25M | 3.02M | 2.78M |
| Receivables | 68.00K | 15.00K | 521.00K | 866.00K |
| OtherReceivables | 68.00K | 15.00K | 521.00K | 866.00K |
| CashCashEquivalentsAndShortTermInvestments | 15.94M | 34.91M | 32.14M | 41.26M |
| OtherShortTermInvestments | 0.00 | 20.47M | 0.00 | |
| CashAndCashEquivalents | 15.94M | 34.91M | 11.67M | 41.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -27.20M | -28.46M | -23.41M | -22.72M |
| RepaymentOfDebt | -348.00K | -407.00K | -381.00K | -366.00K |
| IssuanceOfCapitalStock | 6.92M | 31.62M | 12.57M | 32.91M |
| CapitalExpenditure | -239.00K | -8.00K | -55.00K | -286.00K |
| IncomeTaxPaidSupplementalData | 184.00K | 120.00K | 46.00K | 35.00K |
| EndCashPosition | 15.94M | 34.91M | 11.67M | 41.26M |
| BeginningCashPosition | 34.91M | 11.67M | 41.26M | 31.22M |
| EffectOfExchangeRateChanges | 1.60M | -522.00K | 1.96M | -254.00K |
| ChangesInCash | -20.57M | 23.77M | -31.55M | 10.30M |
| FinancingCashFlow | 6.64M | 31.99M | 12.21M | 33.02M |
| CashFlowFromContinuingFinancingActivities | 6.64M | 31.99M | 12.21M | 33.02M |
| ProceedsFromStockOptionExercised | 65.00K | 781.00K | 12.00K | 469.00K |
| NetCommonStockIssuance | 6.92M | 31.62M | 12.57M | 32.91M |
| CommonStockIssuance | 6.92M | 31.62M | 12.57M | 32.91M |
| NetIssuancePaymentsOfDebt | -348.00K | -407.00K | -381.00K | -366.00K |
| NetLongTermDebtIssuance | -348.00K | -407.00K | -381.00K | -366.00K |
| LongTermDebtPayments | -348.00K | -407.00K | -381.00K | -366.00K |
| InvestingCashFlow | -239.00K | 20.22M | -20.40M | -286.00K |
| CashFlowFromContinuingInvestingActivities | -239.00K | 20.22M | -20.40M | -286.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 20.23M | -20.35M | 0.00 |
| SaleOfInvestment | 0.00 | 20.23M | 0.00 | 0.00 |
| PurchaseOfInvestment | 0.00 | 0.00 | -20.35M | 0.00 |
| NetPPEPurchaseAndSale | -239.00K | -8.00K | -55.00K | -286.00K |
| PurchaseOfPPE | -239.00K | -8.00K | -55.00K | -286.00K |
| OperatingCashFlow | -26.97M | -28.45M | -23.36M | -22.43M |
| CashFlowFromContinuingOperatingActivities | -26.97M | -28.45M | -23.36M | -22.43M |
| ChangeInWorkingCapital | 3.54M | 1.76M | 391.00K | -908.00K |
| ChangeInOtherWorkingCapital | -276.00K | 228.00K | -17.00K | -194.00K |
| ChangeInOtherCurrentLiabilities | 1.29M | 332.00K | -352.00K | 228.00K |
| ChangeInPayablesAndAccruedExpense | 1.22M | -78.00K | 1.66M | 183.00K |
| ChangeInPrepaidAssets | 1.36M | 777.00K | -1.25M | -349.00K |
| ChangeInReceivables | -53.00K | 506.00K | 345.00K | -776.00K |
| OtherNonCashItems | 139.00K | 71.00K | -76.00K | 92.00K |
| StockBasedCompensation | 2.72M | 2.07M | 2.38M | 3.83M |
| DepreciationAmortizationDepletion | 424.00K | 403.00K | 392.00K | 452.00K |
| DepreciationAndAmortization | 424.00K | 403.00K | 392.00K | 452.00K |
| Depreciation | 424.00K | 403.00K | 392.00K | 452.00K |
| OperatingGainsLosses | -2.08M | -5.00M | -1.60M | 409.00K |
| GainLossOnInvestmentSecurities | -1.24M | -5.29M | 20.00K | -17.00K |
| NetForeignCurrencyExchangeGainLoss | -838.00K | 282.00K | -1.62M | 426.00K |
| NetIncomeFromContinuingOperations | -31.71M | -27.75M | -24.84M | -26.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ONCY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|